Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warner Carr

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Allergy and Asthma Proceedings|August 4, 2012
MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safetyEli O Meltzer, Craig LaForce, Paul Ratner, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 28, 2023
Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study resultsDennis K Ledford, Weily Soong, Warner Carr, et al.
The Journal of Allergy and Clinical Immunology|March 16, 2012
A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitisWarner Carr, Jonathan Bernstein, Phil Lieberman, et al.
Allergy and Asthma Proceedings|March 23, 2010
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitisCraig F LaForce, Warner Carr, Stephen A Tilles, et al.
Allergy & Rhinology (Providence, R.I.)|June 2, 2017
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitisCraig F LaForce, Warner Carr, Stephen A Tilles, et al.
The Journal of Allergy and Clinical Immunology. Global|December 11, 2024
On-treatment clinical remission of severe asthma with real-world longer-term biologic useBradley E Chipps, Njira Lugogo, Warner Carr, et al.
Journal of Asthma and Allergy|May 15, 2024
Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe AsthmaWeily Soong, Bradley E Chipps, Warner Carr, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 17, 2021
Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatmentsJennifer Trevor, Njira Lugogo, Warner Carr, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 11, 2023
Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthmaBradley E Chipps, Weily Soong, Reynold A Panettieri, et al.
The Journal of Allergy and Clinical Immunology|October 22, 2023
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeksVipul Jain, Ana Giménez-Arnau, Koremasa Hayama, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Allergy and Asthma Proceedings|August 4, 2012
MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safetyEli O Meltzer, Craig LaForce, Paul Ratner, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 28, 2023
Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study resultsDennis K Ledford, Weily Soong, Warner Carr, et al.
The Journal of Allergy and Clinical Immunology|March 16, 2012
A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitisWarner Carr, Jonathan Bernstein, Phil Lieberman, et al.
Allergy and Asthma Proceedings|March 23, 2010
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitisCraig F LaForce, Warner Carr, Stephen A Tilles, et al.
Allergy & Rhinology (Providence, R.I.)|June 2, 2017
Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitisCraig F LaForce, Warner Carr, Stephen A Tilles, et al.
The Journal of Allergy and Clinical Immunology. Global|December 11, 2024
On-treatment clinical remission of severe asthma with real-world longer-term biologic useBradley E Chipps, Njira Lugogo, Warner Carr, et al.
Journal of Asthma and Allergy|May 15, 2024
Quality of Life Improvements with Biologic Initiation Among Subspecialist-Treated US Patients with Severe AsthmaWeily Soong, Bradley E Chipps, Warner Carr, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 17, 2021
Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatmentsJennifer Trevor, Njira Lugogo, Warner Carr, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 11, 2023
Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthmaBradley E Chipps, Weily Soong, Reynold A Panettieri, et al.
The Journal of Allergy and Clinical Immunology|October 22, 2023
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeksVipul Jain, Ana Giménez-Arnau, Koremasa Hayama, et al.
Pageof 4